Our Institute for Drug Development (IDD) research team develops new treatments for cancer patients through the integration of programs in translational and clinical sciences.
We provide quality research core services to our NCI-designated cancer center investigators. We conduct direct collaborations with colleagues in the pharmaceutical industry and other academic institutions. We assist cancer center members as well as companies with Federal Drug Administration pre-Investigational New Drug (IND) meetings, designing Investigational New Drug-enabling studies, as well as with writing and submitting the Investigational New Drug application to the Federal Drug Administration. The Institute for Drug Development also has experience with writing New Drug Applications (NDAs), as well as presenting data to the Oncology Drug Advisory Committee (ODAC) to the Federal Drug Administration.
We are funded by NCI grants, other public and private grants and pharmaceutical industry contracts.
We are an academic, nonprofit research organization. We are organized and managed along standard business lines, which means we understand timelines and cost control, as well as the importance of accurate, quality-assured data, dedicated investigators and proprietary issues such as protection of confidential information and intellectual property rights.
More than 20
new FDA-approved cancer drugs developed at the preclinical and clinical stages at IDD
More than 1,400
patients enrolled in early phase clinical trials since 2008.
Investigational New Drug applications for early phase clinical trials.
Phase I trial location
for more than 47 counties in South Texas.
Participating in the IDD Fellowship Program has solidified and specifically prepared me for a dedicated career in clinical oncology research. I want to give back to my country with innovative oncology therapies that benefit underserved populations.
Alex V. Mejia Garcia, M.D., Dominican Republic
Our Research, Fellowships & Clinical Trials
Translational Research: In Vivo
Our laboratory personnel have experience with human and non-human tumor models to evaluate experimental drugs. Our strategy for evaluating new compounds in vivo is to work closely with the sponsor to develop a protocol to evaluate the anti-tumor activity of an agent under optimal conditions.
Translational Research: In Vitro
The Tumor Cell Biology Laboratory evaluates anti-cancer drugs in vitro by using human tumor cell lines in various cell-based assays. Hundreds of tumor cell lines derived from colon, prostate, breast, lung, pancreas, melanoma, unique pediatric cell lines and other tumors are available.